aluates Reports

$ 0.0

Automative

Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: October 2024

Report Code: QYRE-Auto-38O14027

Global Non Alcoholic Steatohepatitis NASH Therapeutics and Diagnostics Market Research Report 2023

BUY CHAPTERS

Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-38O14027

Report

October 2024

Pages:105

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Siemens Healthcare

Celerion

ZyVersa Therapeutics, Inc.

Cisbio

Regeneron Pharmaceuticals Inc

Biopredictive

Echosens

GENFIT

Enterome

NGM Biopharmaceuticals

Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market Size

The global market for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics was estimated to be worth US$ 14620 million in 2023 and is forecast to a readjusted size of US$ 38900 million by 2030 with a CAGR of 15.0% during the forecast period 2024-2030

Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market

Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by region & country, by Type, and by Application.

The Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics.

Market Segmentation

Scope of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market Report

Report Metric	Details
Report Name	Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market
Forecasted market size in 2030	US$ 38900 million
CAGR	15.0%
Forecasted years	2024 - 2030
Segment by Type:	Therapeutics Diagnostics
Segment by Application	Hospital Clinic
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Siemens Healthcare, Celerion, ZyVersa Therapeutics, Inc., Cisbio, Regeneron Pharmaceuticals, Inc., BioPredictive, Echosens, Genfit, Enterome, NGM Biopharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market size in 2030?

Ans: The Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market size in 2030 will be US$ 38900 million.

Who are the main players in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market report?

Ans: The main players in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market are Siemens Healthcare, Celerion, ZyVersa Therapeutics, Inc., Cisbio, Regeneron Pharmaceuticals, Inc., BioPredictive, Echosens, Genfit, Enterome, NGM Biopharmaceuticals

What are the Application segmentation covered in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market report?

Ans: The Applications covered in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market report are Hospital, Clinic

What are the Type segmentation covered in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market report?

Ans: The Types covered in the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics - Market report are Therapeutics, Diagnostics

Recommended Reports

Liver Disease Treatments

Diagnostics & Testing

Metabolic & Genetic Disorders

1 Market Overview

1.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Introduction

1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast

1.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Trends & Drivers

1.3.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry Trends

1.3.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers & Opportunity

1.3.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges

1.3.4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players Revenue Ranking (2023)

2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Company (2019-2024)

2.3 Key Companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Manufacturing Base Distribution and Headquarters

2.4 Key Companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered

2.5 Key Companies Time to Begin Mass Production of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

2.6 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Competitive Analysis

2.6.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Therapeutics

3.1.2 Diagnostics

3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type

3.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, by Type (2019-2030)

3.2.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application

4.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, by Application (2019-2030)

4.2.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region

5.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region (2019-2024)

5.1.3 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region (2025-2030)

5.1.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

5.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

5.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

5.4.2 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

5.5.2 South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

5.6.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value

6.3 United States

6.3.1 United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

6.3.2 United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

6.4.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

6.5.2 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

6.5.3 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

6.6.2 Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

6.7.2 South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

6.8.2 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019-2030

6.9.2 India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

6.9.3 India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Siemens Healthcare

7.1.1 Siemens Healthcare Profile

7.1.2 Siemens Healthcare Main Business

7.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

7.1.4 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)

7.1.5 Siemens Healthcare Recent Developments

7.2 Celerion

7.2.1 Celerion Profile

7.2.2 Celerion Main Business

7.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

7.2.4 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)

7.2.5 Celerion Recent Developments

7.3 ZyVersa Therapeutics, Inc.

7.3.1 ZyVersa Therapeutics, Inc. Profile

7.3.2 ZyVersa Therapeutics, Inc. Main Business

7.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

7.3.4 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)

7.3.5 Cisbio Recent Developments

7.4 Cisbio

7.4.1 Cisbio Profile

7.4.2 Cisbio Main Business

7.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

7.4.4 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)

7.4.5 Cisbio Recent Developments

7.5 Regeneron Pharmaceuticals, Inc.

7.5.1 Regeneron Pharmaceuticals, Inc. Profile

7.5.2 Regeneron Pharmaceuticals, Inc. Main Business

7.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

7.5.4 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)

7.5.5 Regeneron Pharmaceuticals, Inc. Recent Developments

7.6 BioPredictive

7.6.1 BioPredictive Profile

7.6.2 BioPredictive Main Business

7.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

7.6.4 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)

7.6.5 BioPredictive Recent Developments

7.7 Echosens

7.7.1 Echosens Profile

7.7.2 Echosens Main Business

7.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

7.7.4 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)

7.7.5 Echosens Recent Developments

7.8 Genfit

7.8.1 Genfit Profile

7.8.2 Genfit Main Business

7.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

7.8.4 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)

7.8.5 Genfit Recent Developments

7.9 Enterome

7.9.1 Enterome Profile

7.9.2 Enterome Main Business

7.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

7.9.4 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)

7.9.5 Enterome Recent Developments

7.10 NGM Biopharmaceuticals

7.10.1 NGM Biopharmaceuticals Profile

7.10.2 NGM Biopharmaceuticals Main Business

7.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

7.10.4 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (US$ Million) & (2019-2024)

7.10.5 NGM Biopharmaceuticals Recent Developments

8 Industry Chain Analysis

8.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industrial Chain

8.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Model

8.5.2 Sales Channel

8.5.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Siemens Healthcare

Celerion

ZyVersa Therapeutics, Inc.

Cisbio

Regeneron Pharmaceuticals Inc

Biopredictive

Echosens

GENFIT

Enterome

NGM Biopharmaceuticals

List of Tables

Table 1. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Trends

Table 2. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers & Opportunity

Table 3. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges

Table 4. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints

Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Type

Table 9. Key Companies Time to Begin Mass Production of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics

Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region (2019-2024) & (%)

Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, (2025-2030) & (US$ Million)

Table 31. Siemens Healthcare Basic Information List

Table 32. Siemens Healthcare Description and Business Overview

Table 33. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

Table 34. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business of Siemens Healthcare (2019-2024)

Table 35. Siemens Healthcare Recent Developments

Table 36. Celerion Basic Information List

Table 37. Celerion Description and Business Overview

Table 38. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

Table 39. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business of Celerion (2019-2024)

Table 40. Celerion Recent Developments

Table 41. ZyVersa Therapeutics, Inc. Basic Information List

Table 42. ZyVersa Therapeutics, Inc. Description and Business Overview

Table 43. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

Table 44. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business of ZyVersa Therapeutics, Inc. (2019-2024)

Table 45. ZyVersa Therapeutics, Inc. Recent Developments

Table 46. Cisbio Basic Information List

Table 47. Cisbio Description and Business Overview

Table 48. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

Table 49. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business of Cisbio (2019-2024)

Table 50. Cisbio Recent Developments

Table 51. Regeneron Pharmaceuticals, Inc. Basic Information List

Table 52. Regeneron Pharmaceuticals, Inc. Description and Business Overview

Table 53. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

Table 54. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business of Regeneron Pharmaceuticals, Inc. (2019-2024)

Table 55. Regeneron Pharmaceuticals, Inc. Recent Developments

Table 56. BioPredictive Basic Information List

Table 57. BioPredictive Description and Business Overview

Table 58. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

Table 59. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business of BioPredictive (2019-2024)

Table 60. BioPredictive Recent Developments

Table 61. Echosens Basic Information List

Table 62. Echosens Description and Business Overview

Table 63. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

Table 64. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business of Echosens (2019-2024)

Table 65. Echosens Recent Developments

Table 66. Genfit Basic Information List

Table 67. Genfit Description and Business Overview

Table 68. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

Table 69. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business of Genfit (2019-2024)

Table 70. Genfit Recent Developments

Table 71. Enterome Basic Information List

Table 72. Enterome Description and Business Overview

Table 73. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

Table 74. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business of Enterome (2019-2024)

Table 75. Enterome Recent Developments

Table 76. NGM Biopharmaceuticals Basic Information List

Table 77. NGM Biopharmaceuticals Description and Business Overview

Table 78. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Products, Services and Solutions

Table 79. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business of NGM Biopharmaceuticals (2019-2024)

Table 80. NGM Biopharmaceuticals Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Downstream Customers

Table 84. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Picture

Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 4. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Report Years Considered

Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2023

Figure 7. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Therapeutics Picture

Figure 9. Diagnostics Picture

Figure 10. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Hospital

Figure 13. Product Picture of Clinic

Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value Market Share by Application, 2023 & 2030

Figure 16. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 18. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 19. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 20. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 21. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 22. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 23. South America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 24. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)

Figure 25. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030

Figure 26. Key Countries/Regions Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value (%), (2019-2030)

Figure 27. United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 28. United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 29. United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 30. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 31. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 32. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 33. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 34. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 35. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 36. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 37. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 38. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 39. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 40. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 41. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 42. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 43. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 44. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 45. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)

Figure 46. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030

Figure 47. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030

Figure 48. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industrial Chain

Figure 49. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Manufacturing Cost Structure

Figure 50. Channels of Distribution (Direct Sales, and Distribution)

Figure 51. Bottom-up and Top-down Approaches for This Report

Figure 52. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Non alcoholic Steatohepatitis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Nonalcoholic Steatohepatitis NASH Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Nonalcoholic Steatohepatitis Diagnostic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global NASH Non alcoholic Steatohepatitis Biomarkers Market Research Report 2024

Global Non Alcoholic Steatohepatitis Treatment Market Research Report 2025

Global Non Alcoholic Fatty Liver Disease Treatment Market Research Report 2024

Global Non Alcoholic Steatohepatitis NASH Treatment Market Insights Forecast to 2030

Fatty Liver Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Non alcoholic Steatohepatitis NASH Biomarkers Market Research Report 2024

Nonalcoholic Steatohepatitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Non Alcoholic Steatohepatitis Biomarkers Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Alcoholic Hepatitis Treatment Market Insights Forecast to 2030

Alcoholic Liver Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Liver Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lipid Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global NASH Therapeutic Drugs Market Insights Forecast to 2030

Lipid Metabolism Disease Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Lipid Metabolism Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Drugs for Lipid Metabolism Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions